RARE DISEASE
Atypical Rett syndrome
Atypical Rett syndrome
Atypical Rett syndrome
Synonyms: Atypical RTT, Rett syndrome variant
Synonyms: Atypical RTT, Rett syndrome variant
Synonyms: Atypical RTT, Rett syndrome variant
Drug discovery
0
drugs
With orphan designations
Overview
Atypical Rett syndrome is a neurodevelopmental disorder caused by MECP2 mutations or other genetic variants (e.g., CDKL5), characterized by partial loss of acquired skills (e.g., hand use, language), gait abnormalities, and stereotypic hand movements. Diagnosis requires ≥2 core symptoms, ≥5 supportive criteria (e.g., scoliosis, sleep disturbances), and exclusion of brain injury. It presents with variable severity, later onset, or incomplete regression compared to classic RTT, affecting ~1/45,000 females. Management focuses on symptom relief and supportive care [7][9][11].
Burden
Progressive motor-behavioral decline: 48.5% pediatric patients require hospitalization/ER visits; adults face higher rates of scoliosis (73.9%) and seizures (56.5%) [4][14].
Lifelong dependency: 80% require assistive devices; 40–60% need gastrostomy feeds or respiratory support [1][4][7].
Economic/emotional strain: High caregiving demands and unmet therapeutic needs despite symptom management [4][7].
Therapies
Multidisciplinary care: Physical/occupational therapy (87% pediatric use), speech-language therapy, and behavioral interventions [1][4].
Medications: Antiepileptics (e.g., carbamazepine), prokinetics for GI motility, melatonin for sleep, and scoliosis management (bracing/surgery) [3][4][7].
Emerging therapies: Gene replacement and RNA/DNA editing in clinical trials [8][13][18].
Categories: rare genetic diseases, rare neurological diseases
Research Papers
279 drug discovery papers about Atypical Rett syndrome, with 4 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
279 drug discovery papers about Atypical Rett syndrome, with 4 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-10 | Translational reading frame predicts the pathogenicity of C-terminal frameshift deletions in MeCP2.
Mutations in the MECP2 gene cause the severe neurological disorder Rett syndrome. A cluster of frameshift-causing C-terminal deletions (CTDs) removes ~100 amino acids and accounts for approximately 10% of RTT-causing mutations. Their pathogenicity is unexpected because this C-terminal domain is dispensable in mice. Analysis of pathogenic and benign human MECP2 variants reveals that some individuals with apparently typical CTDs do not develop Rett syndrome, confirming that C-terminal truncations are not intrinsically pathogenic. Using human sequence data and mouse models we show that pathogenicity results from a marked reduction in MeCP2 levels and depends on the presence of a proline proline stop motif (-PPX) generated by a shift to the +2 reading frame. CTDs that shift to the +1 frame avoid this motif and are benign. Replacing the stop codon of the PPX motif with tryptophan restores MeCP2 expression and rescues RTT-like phenotypes in a CTD mouse model. An adenine base editor efficiently introduces this substitution in cultured cells. These findings define a reliable prognostic distinction between benign and pathogenic CTDs and establish a potential editing strategy for correcting disease-causing CTD mutations.
2026-07-11 | Cellular, electrophysiological and behavioral improvements in a mouse model of Rett syndrome following gene therapy combined with focused ultrasound-mediated blood-brain barrier opening.
Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder due to pathogenic variants in the methyl CpG binding protein 2 gene (MECP2). The discovery that deficits resulting from Mecp2 loss are reversible in mice has increased interest in gene therapy as a potential cure for RTT. We have previously evaluated the efficacy of a self-complementary AAV9 vector expressing a codon-optimized version of Mecp2 (scAAV9-MCO) delivered via a systemic approach in early symptomatic Mecp2-knock-out male (KO) mice. In the present study, focused ultrasound (FUS) was used to transiently disrupt the blood-brain barrier (BBB) in a RTT mouse model, thereby facilitating enhanced AAV delivery to the central nervous system (CNS). Our findings demonstrate that scAAV9-MCO administration, when combined with FUS, significantly improves survival, body weight, respiratory function, and locomotor activity, while restoring the excitatory-inhibitory synaptic balance in hippocampal neurons in treated KO mice relative to untreated animals. Quantification of the brain infection level revealed that 20-40% of cells are Mecp2-positive in the brain of KO mice following the treatment with scAAV9-MCO and FUS. This is a significant improvement compared to prior results without FUS. The evaluation of the protein levels indicates a possible overdose of Mecp2 protein in the brain cells. Nevertheless, these results demonstrate that using FUS following systemic administration of an AAV9 vector represents a significant improvement over classical gene therapy protocol for RTT.
2026-06-15 | Reduction in Seizure Generalization Associated With Long-Term Low-Dose Immunomodulatory Therapy Using Prednisolone and Methotrexate in Rett Syndrome: A Case Report.
Rett syndrome is a severe neurodevelopmental disorder most commonly associated with pathogenic variants of the MECP2 gene and frequently accompanied by epilepsy. Seizures occur in a substantial proportion of patients and may be resistant to conventional antiepileptic therapy. Emerging evidence suggests that neuroinflammatory processes may contribute to seizure propagation and represent a potential therapeutic target. A girl born at term with initially normal early development is described. At approximately 2 years of age, she developed regression of speech and stereotypic hand movements, accompanied by seizures and other neurological features consistent with Rett syndrome. The patient received long-term therapy consisting of low-dose prednisolone and methotrexate in addition to anticonvulsant treatment. During follow-up, a reduction in seizure generalization and a shift in seizure pattern were observed, with generalized seizures becoming less frequent and replaced by brief focal seizures without secondary generalization. In this single case, long-term low-dose prednisolone and methotrexate therapy was associated with a reduction in seizure generalization. Although a causal relationship cannot be established, this observation supports the hypothesis that immunomodulatory mechanisms may influence seizure propagation in pharmacoresistant epilepsy.
2026-06-01 | Heat shock factor 1 signaling: A novel pathway implicated in Rett syndrome pathophysiology
Rett syndrome (RTT) is a neurodevelopmental disorder that is associated with loss-of-function mutations in the methyl CpG binding protein 2 ( MECP2 ) gene. MECP2 regulates transcription both locally and globally, making it challenging to distinguish between genes that are pathogenic and those that constitute transcriptional noise. A rare subpopulation of patients lack MECP2 mutations despite presenting with sufficient symptoms to warrant a clinical diagnosis of RTT. These patients are classified as having atypical and MEPC2 mutation-negative forms of the disorder. We hypothesized that identifying pathways with conserved disruption between typical and atypical forms of RTT would be a viable mechanism to reduce transcriptional noise and identify which genes are most critical to their shared clinical presentation. To test this theory, we conducted differential RNA sequencing using five atypical RTT, six typical RTT (R255X), and nine neurotypical control temporal cortex autopsy samples. Pathways associated with heat shock factor 1 (HSF1) signaling were among the most enriched in both RTT populations. Validation studies using 37 patient temporal cortex samples showed that increased HSF1 signaling was enriched in those with classically severe MECP2 mutations. To investigate whether increased HSF1 signaling is compensatory or pathogenic, we conducted in vivo hyperthermia experiments complemented by cellular stress array analyses. These experiments established that RTT model mice exhibit faster and larger induction of cellular stress-associated proteins. Pharmacological induction of HSF1 in Mecp2 +/- mice was consistent with hyperthermia experiments, showing seizure-like phenotypes and lethality. Conversely, chronic inhibition of HSF1 signaling improved RTT-like phenotypes in domains of motor learning and general health. Together, these data suggest that promiscuous HSF1 signaling is likely a pathogenic amplifier of severe phenotypes and provide a rationale that inhibiting this pathology may hold therapeutic potential in RTT and related disorders. Significance statement Rett syndrome (RTT) is a devastating neurodevelopmental disorder with limited therapeutic options. This manuscript identifies Heat shock factor 1 (HSF1)-signaling a novel therapeutic target and proposes a molecular mechanism by which cellular stress responses are regulated in RTT.
2026-05-11 | Toward an NGF-based therapy for Rett syndrome.
Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by mutations in the MECP2 gene. Although recent therapeutic advances, such as the approval of Trofinetide, offer partial relief, no comprehensive curative treatment is currently available. Among the emerging strategies, nerve growth factor (NGF) has gained attention due to its neurotrophic and immunomodulatory properties. This review, in addition to discussing the key features of RTT and the role of growth factors, also highlights recent evidence supporting NGF-based strategies for RTT, focusing on two independent studies that tested intranasal administration of NGF-like molecules in Mecp2-mutant mice. Both recombinant human NGF (rhNGF) and a modified, "painless" variant (hNGFp) improved behavioral (cognitive and motor) symptoms. While rhNGF primarily restored mitochondrial function, hNGFp restored neuroinflammatory responses through microglial regulation. Despite differences in molecular mechanisms and dosages, both molecules demonstrated efficacy without adverse effects, especially when administered intranasally, preventively, and over longer periods. These findings suggest that NGF may act through dual mechanisms, by supporting energy homeostasis and regulating immune responses. The use of intranasal delivery further enhances translational potential by overcoming blood-brain barrier limitations. Together, these studies provide a strong rationale for pursuing NGF-based therapies in RTT and encourage further investigations to optimize dosing, timing, and safety in preclinical and clinical settings.
2026-08-10 | Translational reading frame predicts the pathogenicity of C-terminal frameshift deletions in MeCP2.
Mutations in the MECP2 gene cause the severe neurological disorder Rett syndrome. A cluster of frameshift-causing C-terminal deletions (CTDs) removes ~100 amino acids and accounts for approximately 10% of RTT-causing mutations. Their pathogenicity is unexpected because this C-terminal domain is dispensable in mice. Analysis of pathogenic and benign human MECP2 variants reveals that some individuals with apparently typical CTDs do not develop Rett syndrome, confirming that C-terminal truncations are not intrinsically pathogenic. Using human sequence data and mouse models we show that pathogenicity results from a marked reduction in MeCP2 levels and depends on the presence of a proline proline stop motif (-PPX) generated by a shift to the +2 reading frame. CTDs that shift to the +1 frame avoid this motif and are benign. Replacing the stop codon of the PPX motif with tryptophan restores MeCP2 expression and rescues RTT-like phenotypes in a CTD mouse model. An adenine base editor efficiently introduces this substitution in cultured cells. These findings define a reliable prognostic distinction between benign and pathogenic CTDs and establish a potential editing strategy for correcting disease-causing CTD mutations.
2026-07-11 | Cellular, electrophysiological and behavioral improvements in a mouse model of Rett syndrome following gene therapy combined with focused ultrasound-mediated blood-brain barrier opening.
Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder due to pathogenic variants in the methyl CpG binding protein 2 gene (MECP2). The discovery that deficits resulting from Mecp2 loss are reversible in mice has increased interest in gene therapy as a potential cure for RTT. We have previously evaluated the efficacy of a self-complementary AAV9 vector expressing a codon-optimized version of Mecp2 (scAAV9-MCO) delivered via a systemic approach in early symptomatic Mecp2-knock-out male (KO) mice. In the present study, focused ultrasound (FUS) was used to transiently disrupt the blood-brain barrier (BBB) in a RTT mouse model, thereby facilitating enhanced AAV delivery to the central nervous system (CNS). Our findings demonstrate that scAAV9-MCO administration, when combined with FUS, significantly improves survival, body weight, respiratory function, and locomotor activity, while restoring the excitatory-inhibitory synaptic balance in hippocampal neurons in treated KO mice relative to untreated animals. Quantification of the brain infection level revealed that 20-40% of cells are Mecp2-positive in the brain of KO mice following the treatment with scAAV9-MCO and FUS. This is a significant improvement compared to prior results without FUS. The evaluation of the protein levels indicates a possible overdose of Mecp2 protein in the brain cells. Nevertheless, these results demonstrate that using FUS following systemic administration of an AAV9 vector represents a significant improvement over classical gene therapy protocol for RTT.
2026-06-15 | Reduction in Seizure Generalization Associated With Long-Term Low-Dose Immunomodulatory Therapy Using Prednisolone and Methotrexate in Rett Syndrome: A Case Report.
Rett syndrome is a severe neurodevelopmental disorder most commonly associated with pathogenic variants of the MECP2 gene and frequently accompanied by epilepsy. Seizures occur in a substantial proportion of patients and may be resistant to conventional antiepileptic therapy. Emerging evidence suggests that neuroinflammatory processes may contribute to seizure propagation and represent a potential therapeutic target. A girl born at term with initially normal early development is described. At approximately 2 years of age, she developed regression of speech and stereotypic hand movements, accompanied by seizures and other neurological features consistent with Rett syndrome. The patient received long-term therapy consisting of low-dose prednisolone and methotrexate in addition to anticonvulsant treatment. During follow-up, a reduction in seizure generalization and a shift in seizure pattern were observed, with generalized seizures becoming less frequent and replaced by brief focal seizures without secondary generalization. In this single case, long-term low-dose prednisolone and methotrexate therapy was associated with a reduction in seizure generalization. Although a causal relationship cannot be established, this observation supports the hypothesis that immunomodulatory mechanisms may influence seizure propagation in pharmacoresistant epilepsy.
2026-06-01 | Heat shock factor 1 signaling: A novel pathway implicated in Rett syndrome pathophysiology
Rett syndrome (RTT) is a neurodevelopmental disorder that is associated with loss-of-function mutations in the methyl CpG binding protein 2 ( MECP2 ) gene. MECP2 regulates transcription both locally and globally, making it challenging to distinguish between genes that are pathogenic and those that constitute transcriptional noise. A rare subpopulation of patients lack MECP2 mutations despite presenting with sufficient symptoms to warrant a clinical diagnosis of RTT. These patients are classified as having atypical and MEPC2 mutation-negative forms of the disorder. We hypothesized that identifying pathways with conserved disruption between typical and atypical forms of RTT would be a viable mechanism to reduce transcriptional noise and identify which genes are most critical to their shared clinical presentation. To test this theory, we conducted differential RNA sequencing using five atypical RTT, six typical RTT (R255X), and nine neurotypical control temporal cortex autopsy samples. Pathways associated with heat shock factor 1 (HSF1) signaling were among the most enriched in both RTT populations. Validation studies using 37 patient temporal cortex samples showed that increased HSF1 signaling was enriched in those with classically severe MECP2 mutations. To investigate whether increased HSF1 signaling is compensatory or pathogenic, we conducted in vivo hyperthermia experiments complemented by cellular stress array analyses. These experiments established that RTT model mice exhibit faster and larger induction of cellular stress-associated proteins. Pharmacological induction of HSF1 in Mecp2 +/- mice was consistent with hyperthermia experiments, showing seizure-like phenotypes and lethality. Conversely, chronic inhibition of HSF1 signaling improved RTT-like phenotypes in domains of motor learning and general health. Together, these data suggest that promiscuous HSF1 signaling is likely a pathogenic amplifier of severe phenotypes and provide a rationale that inhibiting this pathology may hold therapeutic potential in RTT and related disorders. Significance statement Rett syndrome (RTT) is a devastating neurodevelopmental disorder with limited therapeutic options. This manuscript identifies Heat shock factor 1 (HSF1)-signaling a novel therapeutic target and proposes a molecular mechanism by which cellular stress responses are regulated in RTT.
2026-05-11 | Toward an NGF-based therapy for Rett syndrome.
Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by mutations in the MECP2 gene. Although recent therapeutic advances, such as the approval of Trofinetide, offer partial relief, no comprehensive curative treatment is currently available. Among the emerging strategies, nerve growth factor (NGF) has gained attention due to its neurotrophic and immunomodulatory properties. This review, in addition to discussing the key features of RTT and the role of growth factors, also highlights recent evidence supporting NGF-based strategies for RTT, focusing on two independent studies that tested intranasal administration of NGF-like molecules in Mecp2-mutant mice. Both recombinant human NGF (rhNGF) and a modified, "painless" variant (hNGFp) improved behavioral (cognitive and motor) symptoms. While rhNGF primarily restored mitochondrial function, hNGFp restored neuroinflammatory responses through microglial regulation. Despite differences in molecular mechanisms and dosages, both molecules demonstrated efficacy without adverse effects, especially when administered intranasally, preventively, and over longer periods. These findings suggest that NGF may act through dual mechanisms, by supporting energy homeostasis and regulating immune responses. The use of intranasal delivery further enhances translational potential by overcoming blood-brain barrier limitations. Together, these studies provide a strong rationale for pursuing NGF-based therapies in RTT and encourage further investigations to optimize dosing, timing, and safety in preclinical and clinical settings.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.